{"id":3690,"date":"2014-01-23T15:14:37","date_gmt":"2014-01-23T15:14:37","guid":{"rendered":"\/?p=3690"},"modified":"2014-01-23T15:14:42","modified_gmt":"2014-01-23T15:14:42","slug":"intellicell-biosciences-inc-otcmktssvfc-slides-back-as-novelty-wears-out","status":"publish","type":"post","link":"\/articles\/intellicell-biosciences-inc-otcmktssvfc-slides-back-as-novelty-wears-out\/","title":{"rendered":"Intellicell Biosciences, Inc. (OTCMKTS:SVFC) Slides Back as Novelty Wears Out"},"content":{"rendered":"

Predictably, the good days wore out for Intellicell Biosciences, Inc. (OTCMKTS:SVFC<\/a>), the double-zero stem cell company that rose on a promotion and general optimism. SVFC<\/a> slid down more than 33% to $0.0049, on selling volumes above $1.67 million. With such a low price, even one day of delay in PR or promotions will cost a lot. \"SVFC2004.png\" <\/p>\n

Investors are becoming more and more impatient with SVFC<\/a>, as the company has accumulated too much debt, which it did not manage to clear despite the stock dilution. Now, despite the good intentions, SVFC<\/a> is lining up as an erratic double-zero ticker with little potential to hold onto sufficient volumes. The wild price fluctuations and the slim trading may terminally scare investors away.\"ACTC2004.png\"<\/p>\n

The company has given a New York address in an expensive-looking business district, yet it is unknown if the swanky destination will lead to success. Still, in 2012 SVFC<\/a> announced that it had certified its laboratory with the Biologic Consultant Group, and so at least SVFC<\/a> has announced a base for further research.<\/p>\n

The activity for SVFC<\/a> started to take off last October, and though the longer-term chart looks flat, there is a clustering of buyers at the beginning of the new year, signaling new hope for the company. But the worries won’t stop unless SVFC<\/a> ends the money drain and closes up the debt:<\/p>\n